Mean platelet volume predicts early death in acute pulmonary embolism

Kostrubiec, Maciej; Labyk, Andrzej; Pedowska-Wloszek, Justyna; Hrynkiewicz-Szymáska,, Anna; Pacho, Szymon; Jankowski, Krzysztof; Lichodziejewska, Barbara; Pruszczyk, Piotr
March 2010
Heart;Mar2010, Vol. 96 Issue 6, p460
Academic Journal
Background Recently, mean platelet volume (MPV) was reported to predict venous thromboembolism. Moreover, MPV correlates with platelet reactivity and indicates poor outcome in acute coronary syndromes. Objective To examine the hypothesis that in acute pulmonary embolism (APE) MPV is elevated and may predict mortality. Methods and results The study included consecutive 192 patients with APE, (79M/113F, 64±18 years) and 100 controls matched for age, sex and concomitant diseases. On admission blood samples were collected for MPV and troponin measurements. Although MPV did not differ between patients with APE and controls (10.0±1.2 vs 10.1±0.8 fl), it differed between low- and intermediate- or high-risk APE (9.4±1.2 fl, 10.3±1.1 fl, 10.3±1.8 fl; respectively, p<0.0001). Eighteen (9%) patients with APE died during the 30-day observation. MPV was higher in non-survivors than survivors (10.7±1.4 fl vs 9.9±1.2 fl, p<0.01). The areas under receiver operating characteristic curves of MPV were 0.658 (95% CI 0.587 to 0.725) for predicting 30-day mortality, and 0.712 (95% CI 0.642 to 0.775) for 7-day mortality. MPV >10.9 fl, showed sensitivity, specificity, positive predictive value and negative predictive value for death within 30 days (39%, 81%, 18%, 93%, respectively) and for 7-day mortality (54%, 82%, 18%, 96%). Multivariable analysis showed that MPV was an independent mortality predictor for 7- and 30-day all-cause mortality (HR=2.0 (95% CI 1.3 to 3.0), p<0.001)) and 1.7 (95% CI 1.2 to 2.5), p<0.01)), respectively). MPVs were higher in patients with myocardial injury than in those without troponin elevation (10.2±1.1 fl vs 9.8±1.2 fl; p=0.02). There were correlations between MPV and right ventricular diameter and right ventricular dysfunction (r=0.28, p<0.01 and r=0.19, p<0.02, respectively). Conclusion MPV is an independent predictor of early death in APE. Moreover, MPV in APE is associated with right ventricular dysfunction and myocardial injury.


Related Articles

  • Obesity Does Not Increase Mortality after Emergency Surgery. Ferrada, Paula; Anand, Rahul J.; Malhotra, Ajai; Aboutanos, Michel // Journal of Obesity;2014, Vol. 2014, p1 

    Objective. The aim of this study is to evaluate the impact of obesity on patient outcomes after emergency surgery. Methods. A list of all patients undergoing emergent general surgical procedures during the 12 months ending in July 2012 was obtained from the operating room log. A chart review was...

  • Increased platelet sodium-hydrogen exchanger activity in patients with variant angina. Lanza, G.A.; De Candia, E.; Romagnoli, E.; Messano, L.; Sestito, A.; Landolfi, R.; Crea, F.; Maseri, A. // Heart;Aug2003, Vol. 89 Issue 8, p935 

    Discusses results of a study investigating platelet-sodium hydrogen exchange activity in patients with variant angina. Blood analysis protocol; Fluorescence labelling of platelets; Stimulation of sodium-hydrogen exchange.

  • Glycoprotein IIb/IIIa inhibitors and acute coronary syndromes: summary report of the full submission ot NICE, and beyond. Manoharan, G.; Adgey, A. A. J. // Heart;Sep2001, Vol. 86 Issue 3, p259 

    Acute coronary syndromes constitute a spectrum of clinical conditions and can be divided into non-ST segment elevation and ST segment elevation myocardial infarction. Hospital admissions for unstable angina are increasing and have now exceeded those for acute myocardial infarction, with the...

  • Oral Antiplatelet Therapy for Acute and Chronic Management of NSTE ACS: Residual Ischemic Risk and Opportunities for Improvement. Marc Cohen // Cardiovascular Drugs & Therapy;Dec2009, Vol. 23 Issue 6, p489 

    Abstract Introduction  Non-ST-segment elevation acute coronary syndromes (NSTE ACS) are highly prevalent in the United States and globally, and are associated with significant morbidity and mortality. Discussion  The key role of platelet-mediated thrombosis in...

  • Benefits and limitations of current antiplatelet therapies. Nappi, Jean // American Journal of Health-System Pharmacy;7/1/2008, Vol. 65 Issue 13, pS5 

    Purpose. The benefits and limitations of current antiplatelet therapies in the management of patients experiencing acute coronary syndrome (ACS) are reviewed. Summary. Antiplatelet agents, including aspirin, thienopyridines, and platelet glycoprotein (GP) IIb/IIIa receptor inhibitors, have...

  • Successful Low-Dose Thrombolysis of Submassive Pulmonary Embolus in a Pregnant Patient: A Case Report. Dhutia, Harshil; Sprigings, David; Shukla, Ami; Llyod, Sue // Cardiology Research;2013, Vol. 4 Issue 4, p168 

    Pulmonary embolus is an important cause of morbidity and mortality during pregnancy with a high case fatality rate. Due to presumed risk of maternal bleeding and fetal complications, thrombolytic therapy is relatively contraindicated during pregnancy. Thrombolysis for pulmonary embolus in...

  • Intracardiac Thrombosis during Adult Liver Transplantation. Moguilevitch, Marina; Broderick, Carlene // Case Reports in Transplantation;2013, p1 

    Intracardiac thrombosis (ICT) and pulmonary embolism (PE) during adult liver transplantation are rare but potentially lethal complications. They are often overlooked because of significant diagnostic challenges. The combination of hemodynamic compromise and transesophageal echocardiography (TEE)...

  • Studies look at hormones and health risks.  // Clinical Advisor;Nov2013, Vol. 16 Issue 11, p26 

    The article reports on findings that do not support the use of estrogen therapy for preventing cardiovascular or other chronic disease as of November 2013. It references a study in the 2013 issue of the"Journal of the American Medical Association" (JAMA). It states that for post-menopausal women...

  • Premature Mortality from Cardiovascular Disease in the Americas – Will the Goal of a Decline of “25% by 2025” be Met? Ordunez, Pedro; Prieto-Lara, Elisa; Pinheiro Gawryszewski, Vilma; Hennis, Anselm J. M.; Cooper, Richard S. // PLoS ONE;29/10/2015, Vol. 10 Issue 10, p1 

    Background: Cardiovascular diseases (CVD) are the underlying cause 1.6 million deaths per year in the Americas, accounting for 30% of total mortality and 38% of by non-communicable deaths diseases (NCDs). A 25% reduction in premature mortality due four main NCDs was targeted by the 2011...


Read the Article


Sign out of this library

Other Topics